Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals

Executive Summary

"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth

You may also be interested in...



Troubled Biotechs: Orexigen, Telik, Trubion

Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.

Impax Labs To Market Pristiq To Neurologists, Implementing Earlier Deal With Wyeth

Co-promotion deal will assist Impax in ramping up its commercial team ahead of the launch of its own branded specialty drugs.

Nektar Starts Major Push In Opioid-Induced Constipation Space

Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel